Lexaria Bioscience -CW25LEXXWPreferred / convertible
13F holders, Q2 2024 (June 30)3holders
0new positions
0sold out
$0.81avg. 13F price*
At the end of Q2 2024, 3 institutions reported holding Lexaria Bioscience -CW25 (LEXXW) in their 13F filings, unchanged from Q1 2024. 0 opened new positions and 0 sold out. The largest holders were UBS Group AG ($76K), CVI Holdings, LLC ($34K) and Clear Street LLC ($81).
- Company
- Lexaria Bioscience -CW25
- CUSIP
- 52886N117
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 93,623 shares bought, net +93,623 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| UBS Group AG | — | Add +94568.7% | 93,722 | $76K |
| CVI Holdings, LLC | — | No change | 41,651 | $34K |
| Clear Street LLC | — | No change | 100 | $81 |
"% of holder's portfolio" is LEXXW's weight in each manager's 13F, not the share of Lexaria Bioscience -CW25 the manager owns.